Skip to main content
Premium Trial:

Request an Annual Quote

NCI's caBIG Team Seeks Input on caGrid 2.0 Roadmap


The National Cancer Institute's Cancer Bioinformatics Grid project is seeking input from the informatics community on the next generation of caGrid, the service-oriented infrastructure that serves as the foundation for the caBIG effort.

In an announcement this week, Ken Buetow, director of the NCI's Center for Biomedical Informatics and Information Technology, said that caBIG is in the process of developing a roadmap for caGrid 2.0 and would like the research community to suggest improvements aimed at expanding the infrastructure’s capabilities to meet evolving research needs.

Buetow said that caGrid 2.0’s developers hope to develop an infrastructure that “lowers barriers to entry for all caGrid stakeholders, leverages the increasingly mature collection of publicly available open source infrastructure, and continues to provide support for caGrid 1.x users and their data.”

The first draft of the roadmap is available for review here. Researchers can download the document along with a community input spreadsheet that they can use to make comments. Researchers can then send the sheet with their comments to [email protected]

The project team plans to review the community’s input and post revised versions of the roadmap every two weeks.

The final version of the roadmap will be presented at the caBIG annual meeting to be held in Washington, DC, Sept. 13–15. Given the time constraints, suggestions for improvements should be received "as soon as possible," NCI said.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.